Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: A global Phase I/II multiple-ascending-dose study

Maria Elisa Mancuso, Davide Matino, Dan Hart, Francisco-Jose Lopez-Jaime, Christophe Schmitt, Amy Shapiro, Giuliana Ventriglia, Anna Kiialainen, Laura Young, Olivier Catalani, Mark Belletrutti, Tom Chu, Jerzy Windyga, Víctor Jiménez-Yuste, Michaela Lehle, Janice Staber

Blood (2025) 146 (Supplement 1): 302.

https://doi.org/10.1182/blood-2025-302

Published: 2025

Journal Articles

Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study

Víctor Jiménez-Yuste, Eunice Tzeng, Elise Lim, Giuliana Ventriglia, Amy D. Shapiro, Johannes Oldenburg, Johnny Mahlangu

Blood (2023) 142 (Supplement 1): 5495.

https://doi.org/10.1182/blood-2023-173016

Published: 2023

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience

Víctor Jiménez-Yuste, Elise Lim, Ketna Mistry, Giuliana Ventriglia, Amy D. Shapiro

Blood (2023) 142 (Supplement 1): 3999.

https://doi.org/10.1182/blood-2023-173081

Published: 2023

Journal Articles

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Claude Négrier, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Víctor Jiménez-Yuste, Benjamin M. Beckermann, Christophe Schmitt, Cedric Hermans, Giuliana Ventriglia, Jerzy Windyga, Anna Kiialainen, Roseline d'Oiron, Paul Moorehead, Vanda Teodoro, Amy D. Shapiro, Johannes Oldenburg

Blood (2021) 138 (Supplement 1): 343.

https://doi.org/10.1182/blood-2021-146009

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Date

Availability

NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: A global Phase I/II multiple-ascending-dose study

Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study

Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: A global Phase I/II multiple-ascending-dose study

Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study

Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only